Search
Eliglustat
go.drugbank.com/drugs/DB09039ApprovedInvestigational[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.
Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideMequinol
go.drugbank.com/drugs/DB09516ApprovedWithdrawnMequinol is a phenol used in various applications. … It is found as an active ingredient in topical drugs used for skin depigmentation indicated for the treatment of solar lentigines.
Categories: Compounds used in a research, industrial, or household settingDibotermin alfa
go.drugbank.com/drugs/DB11639ApprovedInvestigationalDibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … It is implanted in patients undergoing bone surgeries or those with fractures.
Telmisartan
go.drugbank.com/drugs/DB00966ApprovedInvestigationalTelmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. … smooth muscle, ultimately leading to a reduction in arterial blood pressure.
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersHistrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawnAs the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700] … [L41710] GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of sex steroids.
Synonyms: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone, 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-1-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamideRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.
Donislecel
go.drugbank.com/drugs/DB17961Approved[L47166,L47196] The approval of donislecel was based on the safety and effectiveness evaluated in 2 clinical trials with 30 type 1 diabetic patients. … [L47196] Donislecel was approved by the FDA on June 28, 2023, and is available under the brand name LANTIDRA from CellTrans Inc.[L47196]
Categories: Drugs Used in DiabetesChikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigational[A262051] Prior to 2013, chikungunya virus cases and outbreaks had been identified in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. … Chikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus.
Cetalkonium
go.drugbank.com/drugs/DB11583ApprovedWithdrawn[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113] … Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Cetalkonium ionOlmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalIn particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]
Categories: Angiotensin II receptor antagonists, Angiotensin II receptor blockers (ARBs), plain